Cardiome Pharma Corp. (USA) (NASDAQ:CRME)
| CAPS Rating |
|
|---|---|
| Open | $2.54 |
| Previous Close | $2.55 |
| Daily Range | $2.40 - $2.54 |
| 52-Week Range | $1.86 - $6.23 |
| Market Cap | $147.32M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 125,934 |
| Average Daily Volume | 0 |
CRME
VS S&P 500 (SPY)
How do you think CRME will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CRME Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CRME News and Commentary
- 2 Biospecs for 2012 – Blog at The Motley Fool
- The 20 Fastest Growers in Pharma – The Motley Fool
- $50 Billion Left Equity Mutual Funds, Now What? – Blog at The Motley Fool
- Options Trading and Notes Regarding My Holdings – Blog at The Motley Fool
- Switching Partners Provides a Big Shot in the Arm – The Motley Fool
- Mid-Day Update: Stocks Mixed Despite Better-Than-Expected Consumer Confidence Data – NASDAQ
- 3 Top Stocks at Half-Price – The Motley Fool
- Benefit by Imitating Julian Robertson: Bullish on Commodities, China, And Tech – SeekingAlpha
- Value Traps: Are These Stocks Stars in Disguise or Falling Knives? – The Motley Fool
- UPDATE: Cardiome Partner Plans Continued Oral Vernakalant Development – SmartMoney
- Cardiome Partner Confirms Development Plans For Oral Vernakalant – SmartMoney
- Goodwill in Asset Value: Its Impact on 33 Stocks – SeekingAlpha
- Lilly Antibody Fails in Diabetes Trial: Biotech's Latest Tribulations – SeekingAlpha
- UPDATE: Cardiome Trial Halted After 'Serious' Problem – SmartMoney
- Cardiome Partner Halts Trial Enrollment After 'Serious' Problem – SmartMoney
- Cardiome Receives European Approval For Key Heart Drug – SmartMoney
- Merck, Cardiome Get European Panel's Support For Brinavess – SmartMoney
- 5-Star Stocks on the Upswing – The Motley Fool
- A Little Distracted, Are You, Merck? – The Motley Fool
- Good Luck, Genzyme -- You'll Need It – The Motley Fool
RSS Headlines
Fool UK
